1. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study
- Author
-
Zhan Shi, Jin Huang, Jia Liu, Nannan Shi, Xiaohui Zhang, Liying Chen, Ning Liang, Yong Hou, Kaijun Yang, Kai Zheng, Yang Zhao, Yingchun Zhou, Lin Tong, Heng Gu, Liufen Mo, Gongqi Zhang, Xiaomei Hu, Fangli Song, Jinbo Zhang, Hongming Xu, Hui Na, Qiao Feng, H. S. Chen, Honggang Yi, Yongyan Wang, Youwen Ge, Yan Ma, Chun Yang, Liang Ji, Shusen Zhao, Zhang Liu, Chunyan Li, Yunhong Hu, Wanying Zhao, Huamin Zhang, Ya Mao, Yinzhen Wang, Li Li, Wei Wu, Renbo Chen, Hao Gu, Yipin Fan, Yingjie Zhi, Mingxuan Wang, Xiao Lei, Shengli Yuan, Shoufang Xu, Liwen Jiao, Lanping Wu, Yanhua Xiao, Wei Wang, Junteng Zhu, Haihao Jin, Minqing Li, Guifen Hu, Yibai Xiong, Shaowen Tang, Yuting Ma, Guihui Wu, Qiuhua Huang, Haijun Xie, Xiaoyan Wang, Sheng Sun, Quntang Li, Yaxin Tian, Ruixia Xue, Yanping Wang, Jinping Liu, Jike Li, Bin Liu, Hongde Liu, Jiangfeng Bai, Shaozhen Huang, Yuan Kuang, Puye Yang, Xianyong Li, Linsong Zhang, Guangxi Li, Tuanmao Guo, Chen Zhao, Jingwei Wang, Huizhen Li, Yuanyuan Li, Dongting Wang, Ruili Huo, Zhifei Wang, Tianqing Zhu, Hongmei Wo, Weiguo Bai, Sihong Liu, Jingya Wang, and Yudong Wang
- Subjects
Male ,0301 basic medicine ,RT-PCR, reverse transcription-polymerase-chain-reaction ,Decoction ,Disease ,Cohort Studies ,0302 clinical medicine ,Early treatment ,Prospective cohort study ,COVID-19, coronavirus disease 2019 ,Aged, 80 and over ,Hazard ratio ,RBC, red blood cell ,Middle Aged ,CT, computed tomography ,Treatment Outcome ,030220 oncology & carcinogenesis ,CRP, C-reactive protein ,Female ,Qingfei Paidu decoction ,WBC, white blood cell ,Cohort study ,Unadj., unadjusted ,Adult ,SARS-COV-2, severe acute respiratory syndrome-coronavirus 2 ,China ,medicine.medical_specialty ,Ref., reference ,Article ,Time-to-Treatment ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,IFN, interferon ,QFPDD, Qingfei Paidu Decoction ,Viral shedding ,Adj., adjusted ,PO2, partial pressure of oxygen ,ComputingMethodologies_COMPUTERGRAPHICS ,Aged ,ESR, erythrocyte sedimentation rate ,Pharmacology ,business.industry ,COVID-19 ,Length of Stay ,No., number of patients ,HR, hazard ratio ,Confidence interval ,COVID-19 Drug Treatment ,CI, confidence interval ,030104 developmental biology ,COPD, chronic obstructive pulmonary disease ,SpO2, blood oxygen saturation ,Sample size determination ,WISP, work information system platform ,business ,Drugs, Chinese Herbal ,Follow-Up Studies - Abstract
Graphical abstract, The coronavirus disease 2019 (COVID-19) epidemic has been almost controlled in China under a series of policies, including “early diagnosis and early treatment”. This study aimed to explore the association between early treatment with Qingfei Paidu decoction (QFPDD) and favorable clinical outcomes. In this retrospective multicenter study, we included 782 patients (males, 56 %; median age 46) with confirmed COVID-19 from 54 hospitals in nine provinces of China, who were divided into four groups according to the treatment initiation time from the first date of onset of symptoms to the date of starting treatment with QFPDD. The primary outcome was time to recovery; days of viral shedding, duration of hospital stay, and course of the disease were also analyzed. Compared with treatment initiated after 3 weeks, early treatment with QFPDD after less than 1 week, 1-2 weeks, or 2-3 weeks had a higher likelihood of recovery, with adjusted hazard ratio (HR) (95 % confidence interval [CI]) of 3.81 (2.65–5.48), 2.63 (1.86-3.73), and 1.92 (1.34-2.75), respectively. The median course of the disease decreased from 34 days to 24 days, 21 days, and 18 days when treatment was administered early by a week (P < 0.0001). Treatment within a week was related to a decrease by 1-4 days in the median duration of hospital stay compared with late treatment (P
- Published
- 2020
- Full Text
- View/download PDF